<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2307-3349</journal-id>
<journal-title><![CDATA[Revista de salud publica del Paraguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. salud publica Parag.]]></abbrev-journal-title>
<issn>2307-3349</issn>
<publisher>
<publisher-name><![CDATA[INSTITUTO NACIONAL DE SALUD - MSP Y BS]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2307-33492019000100081</article-id>
<article-id pub-id-type="doi">10.18004/rspp.2019.junio.81-86</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estrategias implementadas en Paraguay para la detección neonatal, diagnóstico y tratamiento de las personas con fibrosis quística]]></article-title>
<article-title xml:lang="en"><![CDATA[Strategies implemented in Paraguay for the neonatal detection, diagnosis and treatment of people with cystic fibrosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ascurra]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz Paranza]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ministerio de Salud Pública y Bienestar Social Programa Nacional de Detección Neonatal ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>9</volume>
<numero>1</numero>
<fpage>81</fpage>
<lpage>86</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2307-33492019000100081&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2307-33492019000100081&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2307-33492019000100081&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La fibrosis quística (FQ) es una patología autosómica recesiva, pasible de ser detectada en el periodo neonatal, causada por mutaciones en el gen regulador de conductancia transmembrana de FQ (CFTR, por sus siglas en inglés), la patología es multisistémica y el tratamiento precoz incide en la expectativa y calidad de vida de los afectados.  Objetivo:  Presentar las principales estrategias y los resultados logrados para la detección, diagnóstico y tratamiento de las personas con FQ, en el Programa Nacional de Detección Neonatal.  Metodología:  Se realizó una revisión del plan operativo anual, informes, publicaciones y documentos emitidos del 2004 al 2018.  Resultado:  En 15 años se ejecutaron 16 estrategias que permitieron la detección, el diagnóstico así como el tratamiento de individuos afectados por la FQ. Entre las que se destacan el desarrollo de un proyecto piloto para el tamizaje de la FQ en RN, mediante dosaje de la tripsina inmunoreactiva (TIR), entrega de una canasta básica de medicamentos, insumos y equipos para el tratamiento de los individuos con FQ detectados por el programa así como los diagnosticados con anterioridad, implementación del test del sudor, elaboración de una Guía Clínica multidisciplinaria, automatización del dosaje de la TIR, que permitió la universalización del screening, y por último la identificación de las mutaciones presentes en los individuos afectados. En el 2015 se logró llegar al 100 % de cobertura de los RN atendidos en los servicios del Ministerio de Salud Pública y Bienestar Social. De enero del 2004 a diciembre del 2018, 179 individuos reciben su tratamiento en el programa, 144 de los cuales fueron detectados en el periodo neonatal.  Conclusión: Las estrategias ejecutadas han tenido resultados muy auspiciosos que nos permitieron universalizar la detección neonatal y tratamiento, lo que conlleva a una mejor calidad y expectativa de vida de los individuos afectados por la FQ. En la actualidad solo faltaría implementar un Centro de Atención Multidisciplinario para las personas con Fibrosis Quística]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Cystic fibrosis (CF) is an autosomal recessive pathology, capable of being detected in the neonatal period, caused by mutations in the CF transmembrane conductance regulator gene (CFTR), the pathology is multisystemic and Early treatment affects the expectation and quality of life of those affected.  Objective: Present the main strategies and the results achieved for the detection, diagnosis and treatment of people with CF, in the National Neonatal Screening Program.  Methodology: A review of the annual operating plan, reports, publications and documents issued from 2004 to 2018 was made.  Result: In 16 years, 16 strategies were implemented that allowed the detection, diagnosis and treatment of individuals affected by CF. Among those that stand out the development of a pilot project for the screening of CF in RN, by means of immunoreactive trypsin (TIR), delivery of a basic basket of medicines, supplies and equipment for the treatment of the individuals with CF detected by the program as well as those previously diagnosed, implementation of the sweat test, elaboration of a multidisciplinary Clinical Guide, automation of the TIR dose, which allowed the universalization of the screening, and finally the identification of the mutations present in the affected individuals . In 2015, it was possible to reach 100% coverage of the RNs assisted in the services of the Ministry of Public Health and Social Welfare. From January 2004 to December 2018, 179 individuals received their treatment in the program, 144 of which were detected in the neonatal period.  Conclusion: The strategies implemented have had very auspicious results that allowed us to universalize neonatal detection and treatment, which leads to a better quality and life expectancy of the individuals affected by CF. At present, it would only be necessary to implement a Multidisciplinary Care Center for people with Cystic Fibrosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Programa]]></kwd>
<kwd lng="es"><![CDATA[Detección neonatal]]></kwd>
<kwd lng="es"><![CDATA[Fibrosis Quística]]></kwd>
<kwd lng="en"><![CDATA[Program]]></kwd>
<kwd lng="en"><![CDATA[Neonatal screening]]></kwd>
<kwd lng="en"><![CDATA[Cystic fibrosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanconi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vehlinger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Knauer]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Das Coeliakie-Syndrombeiangeborenemzystischem Pancreas fibromatose und Bronchiek- tasien]]></article-title>
<source><![CDATA[WienMedWschr]]></source>
<year>1936</year>
<volume>86</volume>
<page-range>753-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[D.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathological study]]></article-title>
<source><![CDATA[Am J Dis Child]]></source>
<year>1938</year>
<volume>56</volume>
<page-range>344-99</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farber]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shwachmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Maddock]]></surname>
<given-names><![CDATA[CL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancreatic function and disease in early life. I. Pancreatic enzyme activity and the celiac syndrome]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1943</year>
<volume>20</volume>
<page-range>827-33</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sant&#8217;Agnese]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Darling]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Shea]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease.]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>1953</year>
<volume>12</volume>
<page-range>549-63</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shwachman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Oski]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Khaw]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The syndrome of pancreatic insufficiency and bone marrow dysfunction.]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>1964</year>
<volume>65</volume>
<page-range>645-63</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Kulczycki</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinton]]></surname>
<given-names><![CDATA[PM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chloride impermeability in cystic fibrosis]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1983</year>
<volume>301</volume>
<page-range>421-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knowles]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Gatzy]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Boucher]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis.]]></article-title>
<source><![CDATA[Eng J Med]]></source>
<year>1981</year>
<volume>305</volume>
<page-range>1489-95</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsiu]]></surname>
<given-names><![CDATA[L.-C]]></given-names>
</name>
<name>
<surname><![CDATA[Zsiga]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Plavsic]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Markiewicz]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Buchwald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cystic fibrosis: progress in mapping the disease locus using polymorphic DNA markers]]></article-title>
<source><![CDATA[I. Cytogenet. Cell. Genet.]]></source>
<year>1985</year>
<volume>29</volume>
<page-range>299-301</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rommens]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Iannuzzi]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Kerem]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Drumm]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Melmer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of the cystic fibrosis gene: Chromosome walking and jumping.]]></article-title>
<source><![CDATA[Science]]></source>
<year>1989</year>
<volume>245</volume>
<page-range>1059-65</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riordan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rommens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kerem]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Alon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rozmahel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grzelczak]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA]]></article-title>
<source><![CDATA[Science]]></source>
<year>1989</year>
<volume>245</volume>
<page-range>1066-73</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerem]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rommens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buchanam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Markewicz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chakrauarti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of thecystic fibrosis gene: Geneticsanalysis]]></article-title>
<source><![CDATA[Science]]></source>
<year>1989</year>
<volume>245</volume>
<page-range>1074-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortigosa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrosis qui&#769;stica. Aspectos diagno&#769;sticos]]></article-title>
<source><![CDATA[ColombMed]]></source>
<year>2007</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-491</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Palac]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bharat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cullina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pricket]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype]]></article-title>
<source><![CDATA[J CystFibros]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>34-42</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Cystic Fibrosis Mutation Database]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Braegger]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Declercq]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pancheva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.]]></article-title>
<source><![CDATA[ClinNutr]]></source>
<year>2016</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>557-77</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Cystic Fibrosis Trust. Nutrition Working Group</collab>
<source><![CDATA[Nutritional Management of Cystic Fibrosis.]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bromley, UK ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gabriela]]></surname>
<given-names><![CDATA[Repetto L]]></given-names>
</name>
<name>
<surname><![CDATA[Helena]]></surname>
<given-names><![CDATA[Poggi M]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[Harris D]]></given-names>
</name>
<name>
<surname><![CDATA[Héctor]]></surname>
<given-names><![CDATA[Navarro M]]></given-names>
</name>
<name>
<surname><![CDATA[Ignacio]]></surname>
<given-names><![CDATA[Sánchez D]]></given-names>
</name>
<name>
<surname><![CDATA[Ernesto]]></surname>
<given-names><![CDATA[Guiraldes C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identificación de mutaciones en el gen CFTR en pacientes chilenos con fibrosis quística.]]></article-title>
<source><![CDATA[Rev. méd. Chile]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[McDougal]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Blackman]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients]]></article-title>
<source><![CDATA[Respir Res]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>140</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Assis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Debray]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gallbladder and bile duct disease in Cystic Fibrosis]]></article-title>
<source><![CDATA[J Cyst Fibros]]></source>
<year>2017</year>
<volume>16</volume>
<page-range>62-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibarra-Gonzalez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez-Morales]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vela-Amieva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-Mogel]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Del Alba]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retos y Oportunidades en la Implementación del Tamiz Neonatal.]]></article-title>
<source><![CDATA[Acta PediatrMex]]></source>
<year>2018</year>
<volume>1</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>35S-46S</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Therrell]]></surname>
<given-names><![CDATA[Borrajo GustavoJC]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[Adams]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status of newborn screening worldwide]]></article-title>
<source><![CDATA[Seminars in Perinatology]]></source>
<year>2015</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>171-87</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borrajo]]></surname>
<given-names><![CDATA[GJC]]></given-names>
</name>
</person-group>
<source><![CDATA[Pesquisa neonatal de enfermedades congénitas]]></source>
<year>2011</year>
<publisher-loc><![CDATA[La Plata ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de la Plata]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Guia Clínica: Fibrosis Quística, Programa de Detección Neonatal]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Asunción, Paraguay ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>OPS/MSPyBS</collab>
<source><![CDATA[Indicadores Básicos de Salud]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castellani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Duff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heijerman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Munck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ratjen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Cystic Fibrosis, Best Practice Guidelines,]]></article-title>
<source><![CDATA[Journal of Cystic Fibrosis]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>153-78</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ascurra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salinas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Porzio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Incidencia de la fibrosis quística en Paraguay]]></source>
<year>2019</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-10</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ascurra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Espinola]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de herramientas moleculares para la detección de mutaciones en personas con fibrosis quística]]></article-title>
<source><![CDATA[Pediatr]]></source>
<year>2018</year>
<volume>45</volume>
<page-range>75</page-range><publisher-loc><![CDATA[Asunción ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
